Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2016

View Archived Issues

Enanta Pharmaceuticals patents FXR agonists

Merck & Co. discloses OX2 receptor antagonists

Sage Therapeutics describes GABA receptor modulators

Eleven Biotherapeutics submits IND for EBI-031, licenses IL-6 technology to Roche

First-in-human data for MGD-010

Wanbang Biopharmaceuticals to prepare IND application for SBM-TFC-039

FDA will review biosimilar application for Amgen's adalimumab

Biosimilar rituximab GP-2013 shows bioequivalence

Clinical trial data delineate activity of pembrolizumab in advanced sarcoma and thyroid cancer

GS-9876: preclinical data

Teva voluntarily suspends sales of Zecuity following adverse application site reactions

Eisai presents latest phase I/II data for E-6011 in rheumatoid arthritis and Crohn's disease

High rate of response seen with SL-401 in blastic plasmacytoid dendritic cell neoplasm

Fibrocell Science starts recruiting patients in study of FCX-007

Revance discontinues development of RT-001 for lateral canthal lines on basis of phase III results

Symic Biomedical reports treatment of first patient with SB-061

Ra Pharmaceuticals discloses phase I results for RA-101495

FDA issues complete response letter for Apadaz

Adamas Pharmaceuticals reports positive results in phase II trial for amantadine

Marinus Pharmaceuticals announces topline results from phase III trial of ganaxolone

Otsuka Pharmaceutical terminates emixustat and OPA-6566 agreements with Acucela

FDA grants fast track designation to ProMetic's IV plasminogen

ContraVir Pharmaceuticals/Ciclofilin Pharmaceuticals merger complete

FDA accepts NDA for CL-108 for review

FDA grants breakthrough therapy designations to Shire's SHP-621 and SHP-625

BioSpecifics Technologies reports positive results on CCH phase II trial

Surface BST2 shows promise as a biomarker for interferon response in patients with SLE

Tyme Technologies begins recruiting for phase Ib/II trial of SM-88

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...